TREATMENT OPTIONS FOR ACUTE COUGH

James Terrell, Pharm.D. Candidate

Cough is the most common reason patients seek medical attention in the United States. Since coughing may be provoked by a number of conditions such as allergies, the common cold, pneumonia, heart failure, or pulmonary embolism, proper diagnosis and treatment can be perplexing. Complicating the matter, many of the drugs available for cough, including the “gold standard” codeine, have failed to show efficacy in recent trials. This review will summarize the current data available for commonly used cough remedies and assess their appropriateness for treating acute cough.

Acute cough refers to any cough, regardless of etiology, that has persisted for less than 3 weeks. Chronic cough is defined as cough that lasts longer than 3 weeks. Current treatment guidelines for chronic cough differ from those of acute cough and will not be discussed in great detail.1

Before treating an acute cough, underlying chronic conditions, such as asthma and GERD, should be ruled out. Also, it is important to ensure that the patient does not have a upper respiratory tract infection, which may warrant antimicrobial therapy. This is especially true due to the recent increase in adult pertussis (whooping cough) throughout the U.S. Finally, the clinician should differentiate productive from non-productive cough. Cough suppressants should be avoided in the former.2

Epidemiology/Etiology

In 2005, a two-year prospective study evaluating 136 children (<18 years old, mean 2.7) with cough, defined as lasting 1-6 weeks, revealed that in 67% of the cases, an infectious agent was present. The results of this study (Table 1), indicate that 58% of cough-associated respiratory infections are caused by viruses.3 However, the small sample size limits the reliability of these findings. In 2001, the World Health Organization (WHO) reported that rhinovirus is responsible for over 50% of colds in adults and that cough symptoms abate in 7-9 days.4

Data on frequency and prevalence of cough is difficult to interpret since many cases go untreated and/or are not reported. In 1985, it was estimated that over 2 billion dollars were spent on over the counter (OTC) cough and cold remedies.4

Physiology of cough

Coughing is a natural defense mechanism that can be mechanically (increased mucus or bronchoconstriction) or chemically induced (capsaicin, histamine, bradykinin, etc). Activation of either of these pathways sends signals to the nucleus tractus solitarius (NTS) which activates the cough reflex via efferent nerve fibers. The cortex can inhibit the NTS allowing some voluntary control. A local pulmonary
Centrally acting antitussives, such as codeine and dextromethorphan, are proven to be an effective cough suppressant in animal models. It is widely accepted that codeine and DM are effective cough suppressants. However, recent data in humans have shown codeine and DM to be ineffective at suppressing cough. These newer studies tend to have larger populations and selectively recruited patients with upper airway disease, the major cause of acute cough.

It has been hypothesized that cough originating in the larynx (i.e., upper airway pathology) uses neural pathways that are less sensitive to codeine and DM, whereas cough originating in the tracheobronchial tree responds well to these drugs. Furthermore, cough associated with upper airway disease are actually “expiration reflexes.” Expiration reflexes are specific to the larynx and are not true coughs in that they are not preceded by a large inhalation. These two hypotheses, which have been demonstrated in animal models, tend to explain why older human trials involving patients with lower airway disease concluded that codeine and DM were effective cough suppressants.

Human studies often utilize a nebulized chemical, like capsaicin or citric acid, to invoke a cough. Antitussive efficacy is then determined by administering the drug, rechallenging with the cough stimulant, and measuring the change in cough frequency and/or intensity. Repeated challenges to citric acid produces less reaction with each exposure, suggesting that the body adapts to it. This adaptation may cause a false change from baseline in cough frequency and intensity, leading investigators to conclude that the intervention is efficacious.

Manap et al administered 30 mg of DM, 60 mg of DM, and placebo to their study group. Citric acid was given every minute for 5 minutes to generate a cough. This was performed every hour for 12 hours. Results indicated 60 mg of DM significantly reduced cough response compared to placebo and 30 mg DM was no different than placebo. This experiment was powered to detect a 10% change in cough frequency. It is unclear whether a 10% change in cough frequency translates into clinically significant improvement. It has been reported that a 20% change is the minimal threshold for clinical improvement.

Lee et al studied 43 adults aged 18-60 (mean 22.9) with recent URTI (<3 weeks) to detect a 20%...
change from baseline. Patients were given either 30 mg DM or placebo. They found no significant difference between the effects of placebo or DM on either 1) cough frequency, expressed as number of coughs per 10 minutes 2) cough intensity, measured by decibel force, or 3) subjective assessment. A major advantage of this study is that disease-induced cough was chosen over chemically stimulated cough. Unfortunately, the study was underpowered to detect a 20% difference between groups due to attrition.

Lee’s study was designed very similar to an earlier experiment that challenged the usefulness of codiene in patients with a recent URTI. Patients were given 50 mg of codeine or placebo and their cough was assessed. No difference was found between the two groups using 1) frequency 2) intensity or 3) subjective assessment.

Trials that found no difference between antitussives and placebo did, however, detect a downward trend in cough symptoms suggesting a placebo effect. The placebo effect can be explained by the patient’s cortical control over the cough reflex. A study by Hutchings et al showed that patients asked to suppress their cough reflex, whether chemically induced or disease related (URTI), can almost completely eliminate it. In acute cough due to upper airway disease, the centrally acting antitussives codeine and dextromethorphan provide very little in terms of cough suppression and that any benefit is due to increased reflex inhibition imparted by cortical control.

Contrary to the findings in these trials, a recent meta-analysis of cough regimens suggested that DM is beneficial in acute cough, since two of the three studies indicated significant findings. These conflicting results underscore the need for newer, sufficiently powered, randomized control trials that utilize cohorts accurately representing the patient population.

H1 antagonists

H1 antagonists like diphenhydramine and chlorpheniramine exert their effects peripherally by preventing mast-cell degranulation and decreasing vascular permeability and bronchoconstriction. By decreasing the vascular permeability, less mucus escapes into the airway; thus, decreasing the frequency of mechanically induced cough. This “drying effect” is also beneficial in patients with post-nasal drip syndrome, the leading cause of chronic cough. These drugs also exhibit anticholinergic and sedative side effects.

Currently, there are little available data sup-
porting the use of an antihistamine as monotherapy to treat acute cough. The current guidelines suggest using a first generation antihistamine combined with a decongestant for cough due to the common cold.\textsuperscript{13} Studies have confirmed that only a combination with a decongestant, like pseudoephedrine, reduces cough frequency.\textsuperscript{14} Non-sedating antihistamines have failed to show a similar benefit.\textsuperscript{15}

Benzonatate

Benzonatate (Tessalon Perles\textsuperscript{®}) is a chemical analog of tetracaine, a local anesthetic. Benzonatate exerts its action by suppressing nerve firing of stretch receptors in the lung endothelium to the NTS. Its onset of action is less than 30 minutes and duration of action may be as long as 8 hours.

The side-effect profile is more extensive than the other available options and includes: sedation, headache, nausea, vomiting, chest numbness, ocular irritation, and nasal congestion. Benzonatate is not FDA approved for cough and the only evidence of its efficacy comes from case reports on opioid-resistant patients with terminal cancer.\textsuperscript{16}

Conclusion

At this point, there is little data to support treating acute cough. Patients suspected of having the common cold could be given an antihistamine/decongestant combination. Patients with a non-productive acute cough of unconfirmed etiology may be offered dextromethorphan or codeine with the understanding that any benefit may be marginal. The side effect profile of codeine may make it less desirable. In addition, many states have enacted laws requiring prescriptions for codeine-containing products, making it more difficult for patients to obtain them. In most cases, dextromethorphan-containing products are a safe option to recommend for these patients. For non-productive cough not due to upper airway infections, codeine and dextromethorphan remain first line agents and should be offered.

References

9. Lee PCL, Jawad MSM, Eccles R. Antitussive

<table>
<thead>
<tr>
<th>Table 3. Pharmacokinetic parameters for centrally-acting antitussives</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Dextromethorphan</strong></td>
</tr>
<tr>
<td>Onset of action</td>
</tr>
<tr>
<td>Duration of action</td>
</tr>
<tr>
<td>Metabolism</td>
</tr>
<tr>
<td>Elimination</td>
</tr>
<tr>
<td>Renal adjustments</td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>

* Active metabolites


Index for Volume 21 (Oct 2005 - Sep 2006)

<table>
<thead>
<tr>
<th>Topic</th>
<th>Issue (Page)</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>Aug 2006 (04)</td>
</tr>
<tr>
<td>Azilect®</td>
<td>Sep 2006 (06)</td>
</tr>
<tr>
<td>Byetta®</td>
<td>Jan 2006 (01)</td>
</tr>
<tr>
<td>Chantix®</td>
<td>Sep 2006 (01)</td>
</tr>
<tr>
<td>Clopidogrel</td>
<td>Apr 2006 (01)</td>
</tr>
<tr>
<td>Community-associated methicillin-resistant staphylococcus aureus (MRSA)</td>
<td>Feb 2006 (01)</td>
</tr>
<tr>
<td>Exenatide</td>
<td>Jan 2006 (01)</td>
</tr>
<tr>
<td>Gout</td>
<td>Mar 2006 (04)</td>
</tr>
<tr>
<td>Herbal supplements in hyperlipidemia</td>
<td>May 2006 (01)</td>
</tr>
<tr>
<td>Insulin detemir</td>
<td>Mar 2006 (01)</td>
</tr>
</tbody>
</table>

K-L-M-N
Levemir® Mar 2006 (01)
Linezolid vs. Vancomycin: Treatment Jul 2006 (01) of skin and soft tissue infections and hospital-acquired pneumonia caused by methicillin-resistant S. aureus (MRSA)
Micafungin Nov 2005 (04)
Mycamine™ Nov 2005 (04)

O-P-Q-R
Phosphodiesterase-5 inhibitors for erectile dysfunction Aug 2006 (01)
Plazix® Apr 2006 (02)
Pramlintide Dec 2005 (01)
Ramelteon Oct 2005 (02)
Ranexa® Jun 2006 (01)
Ranolazine Jun 2006 (01)
Rasagiline Sep 2006 (06)
Requip® Jan 2006 (06)
Rimonabant Aug 2006 (04)
Ropinirole Jan 2006 (05)
Rozerem® Oct 2005 (01)

S-T-U-V
Statin in ACS Nov 2005 (01)
Symlin® Dec 2005 (01)
Vancomycin Jul 2006 (01)
Varenicline Sep 2006 (01)

W-X-Y-Z

The PharmaNote is Published by:
The Department of Pharmacy Services, UF Family Practice Medical Group, Departments of Community Health and Family Medicine and Pharmacy Practice University of Florida

John G. Gums Editor Pharm.D.
R. Whit Curry, M.D. Associate Editor
Shawn Anderson Assistant Editor Pharm.D.